Recent advances in therapies for primary myelofibrosis

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET), are driven by JAK2 signaling.
• PMF and secondary MF are aggressive MPNs with limited curative options beyond stem cell transplantation.
• Current JAK inhibitors offer symptomatic relief but do not significantly alter disease progression.

Purpose of the Study:

• To review current therapeutic strategies for MPNs, focusing on myelofibrosis.
• To explore novel therapeutic approaches targeting disease mechanisms beyond JAK inhibition.
• To identify future treatment directions for modifying MPN progression and improving patient outcomes.

Main Methods:

• Review of current literature on MPN genetics, pathophysiology, and therapeutic agents.
• Analysis of emerging treatments targeting epigenetic regulation, apoptosis, cell cycle, cytokines, and signaling pathways.
• Evaluation of novel strategies including interferon-α, telomerase inhibition, and immunotherapy.

Main Results:

• JAK inhibitors improve symptoms and spleen size in MF but lack disease-modifying effects.
• New agents target specific molecular pathways, aiming to correct cytopenias and inhibit fibrosis.
• Promising approaches include telomerase inhibition, combination therapies (JAK inhibitors with BCL2/BCL-xL or BET inhibitors), and targeted therapies for JAK2V617F, MPL, and calreticulin mutations.

Conclusions:

• Significant advancements are being made in developing disease-modifying treatments for MF.
• Future therapies will likely involve targeted inhibition of specific mutations and pathways, potentially combined with JAK inhibitors.
• Improved understanding of MPN biology is paving the way for more effective and less toxic treatments.